Thank you so much for joining if you were able to make our meeting yesterday. We had wonderful presentations from Dr. Shioda at Boston University and Dr. Ziolkowski from Stanford University about the network studies they are currently leading and recruiting for data partner participation. Please see the recording and meeting notes below.
Meeting Summary-
Clair introduced two key presentations, starting with Dr. Shioda’s study on pediatric vaccination aimed at presenting findings to the WHO. Thamir Alshammari raised a potential conflict of interest due to his membership on the Vaccine Safety Committee at the WHO, but it was clarified that the study focuses on effectiveness rather than safety. Following Dr. Shioda, Dr. Ziolkowski from Stanford will present a study on urine measurements, specifically urine creatinine and protein levels. Clair expressed enthusiasm for this study, emphasizing the need for more measurement values in their research to facilitate discussions and advance network studies among data partners.
Dr. Kayoko Shioda provided an overview of her research on the pneumococcal conjugate vaccine (PCV), discussing its high cost and the importance of quantifying its benefits for public health resource allocation. She highlighted her team’s collaboration with countries in Latin America and Africa to assess the impact of PCV after its introduction and noted the varying dosing schedules used in different regions. Shioda presented the research question of identifying the optimal vaccine dosing schedule, advocating for observational studies to capture real-world data and introducing target trial emulation as a method to enhance comparisons between different dosing schedules.
Clair outlined the methods for determining eligibility in a study, focusing on the use of aggregate summary statistics from data partners. She explained the criteria for identifying suitable databases and mentioned challenges faced by some partners in meeting these measures. The discussion transitioned to Susan’s overview of proteinuria and its implications for kidney health in cancer patients, detailing various testing methods and the need for systematic methodologies in extracting urine measurement values.
Vojtech Huser raised concerns about coding clarity for albuminuria measurements, while Hannah Morgan-Cooper acknowledged ongoing efforts to improve data mapping. The meeting concluded with a focus on collaboration and enhancing data standardization efforts.